Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GemBex phase II study in cutaneous T-cell lymphoma
ISRCTN18563749Phase 2Completed
- Sponsor
- University College London
- Start
- Jul 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and bexarotene in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by University College London. Primary endpoint: Feasibility and efficacy. Started Jul 2008; status: completed.
02
Drugs
gemcitabinebexarotene
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on ISRCTN18563749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18563749.